Date: Sunday 29 - Tuesday 31 October 2023
Venue: Estoril Congress Centre, Portugal
ESH 6th International Conference: Acute Myeloid Leukemia “Molecular and Translational”: Advances in Biology and Treatment The successful biannual ESH Conferences on acute myeloid leukemia (AML) have established themselves as scientific and educational programmes at the interphase of molecular and biologic developments and clinical translation. Novel technological, molecular and immunologic approaches are rapidly creating novel insights into the biology and therapeutic perspectives of AML. The cutting-edge programme of the conference will deal with the molecular and functional features of leukemic stem cells and their interaction with the microenvironment, the role of somatic and germ-line mutations and epigenetic alterations in the biology of AML, the genomics of leukemogenesis, advances in molecular diagnostics and developmental therapeutics with a focus on molecular and immunotherapeutic targeted therapeutics. Special attention will be given to the utility and promise of novel therapeutic agents.
Continuing Medical Education (CME) credit points will be awarded to physicians for the time they will spend at the meeting improving their knowledge and skills. ESH is a provider of the European Haematology CME system.
Posters and Brief Oral Communications:
Registered participants are invited to submit their abstracts. Selected abstracts will be presented as posters.
Call for abstracts: deadline 16 July 2023
This meeting will be valuable to you if you are looking for:
- A cutting-edge scientific program – from basic science to clinical and therapeutic applications and perspectives
- Multiple opportunities for scientific interaction with an international faculty of distinguished experts
- An emphasis on critical discussion The meeting will provide clinicians and scientists with state-of-the-art recommendations regarding patient care and insight in controversies in the field.
The meeting will be of interest to:
- Senior biologists and clinicians, including experts in the field (MD, PhD, MD-PhD)
- Junior scientists and clinicians (MD, PhD)
- PhD candidates and clinical residents still in-training
Upon completion of this CME activity, participants should:
- Understand the pathobiology of leukemia and its development with respect to alterations in hematopoietic stem cells, their microenvironment and altered signal transduction pathways.
- Acquire insight into the possible mechanisms of inherited and preleukemic disorders and genomic instability that predispose to leukemogenesis and predispose also to disease progression.
- Understand the characterisation of a leukemia stem cell and its relationship to disease development and phenotype.
- Learn about the pathobiologic importance of epigenetic dysregulation in the development of acute myeloid leukemia and its clinical impact.
- Evaluate the merits and relevance of molecular diagnostics and minimal residual disease assessment in relation to various management decisions.
- Gain insight into novel therapeutics of acute myeloid leukemia, including knowledge about their mechanisms of action, drug resistance mechanisms, the current developmental status of various targeted drugs and novel antibody-based and cell-transfer based immunotherapeutic approaches and their promises for future clinical application.
- Rare subsets of acute leukaemia
- Tracking leukaemic stem cells (LSCs)
- Routing diagnosis gene expression and mutational profiling
- Addition of a 3rd agent to frontline 7+3
- Allogeneic hematopoietic stem cell transplantation (HSCT)
- Immunotherapy for acute leukaemia
The program will include:
- Plenary Sessions
- Panel Discussions
- Simultaneous Meet the Expert Sessions
- Poster Walks